Latest Breaking News On - Avoro capital - Page 3 : vimarsana.com

Merck & Co., Inc. (NYSE: MRK) Completes Acquisition of Acceleron for $11.5 Billion

Merck & Co., Inc. (NYSE: MRK) Completes Acquisition of Acceleron for $11.5 Billion
journaltranscript.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from journaltranscript.com Daily Mail and Mail on Sunday newspapers.

Canada
Kenneth-frazier
Rob-davis
Acceleron-pharma
Merck-co-inc
Avoro-capital
Transforming-growth-factor

Aadi Bioscience Appoints Brendan Delaney as Chief Operating

Aadi Bioscience Appoints Brendan Delaney as Chief Operating
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United-states
Irina-koffler
Brendan-delaney
Neil-desai
Behzad-aghazadeh
Bristol-myers-squibb
Aadi-bioscience
Genentech
Drug-administration
Gilead-sciences-inc
Aadi-bioscience-inc
Rutgers-university

Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer

Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United-states
Irina-koffler
Brendan-delaney
Neil-desai
Behzad-aghazadeh
Bristol-myers-squibb
Aadi-bioscience
Genentech
Drug-administration
Gilead-sciences-inc
Aadi-bioscience-inc
Rutgers-university

Aadi Bioscience (AADI) Appoints Brendan Delaney as Chief Operating Officer

Aadi Bioscience (AADI) Appoints Brendan Delaney as Chief Operating Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Neil-desai
Brendan-delaney
Behzad-aghazadeh
Bristol-myers-squibb
Aadi-bioscience-inc
Immunomedics-inc
Rutgers-university
Genentech
Constellation-pharmaceuticals
Gilead-sciences-inc
Chief-operating-officer
Chief-commercial-officer

Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform

Press release content from Business Wire. The AP news staff was not involved in its creation. Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform March 12, 2021 GMT BOSTON (BUSINESS WIRE) Mar 12, 2021 Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its platform capabilities to rationally design and develop small molecule degraders (also known as molecular glues) that hijack the body’s innate ability to degrade proteins. Through this approach, Monte Rosa aims to eradicate undruggable proteins that cause or drive the progression of genomically-defined diseases intractable to standard care, including cancer.

Boston
Massachusetts
United-states
Cambridge
Cambridgeshire
United-kingdom
Switzerland
Blackrock
United-kingdom-general
Monte-rosa
Markus-warmuth
Dan-budwick